Table 4. TNFRSF receptor antibodies in clinical trials.
| Antibody | Target | Isotype | Status | ID | Condition | |
|---|---|---|---|---|---|---|
| Brentuximab-Vedotin SGN-35 | CD30 | Drug conjugate, chimerized IgG1 | Approved, >70 studies | — | Lymphoma | |
| XmAb2513 | CD30 | IgG1 Enhanced FcγR binding | Phase 1 | Completed | NCT00606645 | Hodgkin lymphoma Anaplastic large cell lymphoma |
| MDX-1401 | CD30 | IgG1 | Phase 1 | Completed | NCT00634452 | Hodgkin lymphoma |
| HeFi-1 | CD30 | Murine IgG1 Agonist | Phase 1 Phase 1 | Completed Completed | NCT00048880 NCT00003741 | Neoplasms Lymphoma |
| PF-05082566 | 4-1BB | IgG2 Agonist | Phase 1 Phase 1 | Recruiting Recruiting | NCT02179918 NCT01307267 | Advanced solid tumors NHL |
| Urelumab BMS-663513 | 4-1BB | IgG4 Agonist | Phase 1 Phase 1 Phase 1/2 Phase 1 Phase 1 Phase 1 Phase 1 Phase 1/2 Phase 2 | Recruiting Recruiting Recruiting Recruiting Recruiting Terminated Terminated Terminated Completed | NCT01775631 NCT02252263 NCT02253992 NCT01471210 NCT02110082 NCT00461110 NCT00351325 NCT00309023 NCT00612664 | B-cell malignancies Multiple myeloma Advanced solid tumors Advanced B-cell NHL Solid tumors, B-cell NHL CRC, HNC NSCLC Solid malignancies Advanced cancer Melanoma |
| TRX518 | GITR | IgG1 N297 Fc-disabled | Phase 1 | Recruiting | NCT01239134 | Stage III/IV melanoma Solid tumors |
| MK-4166 | GITR | Phase 1 | Recruiting | NCT02132754 | Solid tumors | |
| Varlilumab | CD27 | IgG1 | Phase 1 | Recruiting | NCT01460134 | B-cell malignancies |
| CDX-1127 | Solid tumors | |||||
| Phase 1 | Recruiting | NCT02284971 | Prostate cancer | |||
| Phase 1/2 | Recruiting | NCT02335918 | NSCLC, CRC, HNC, OC, Melanoma | |||
| MEDI6469 | OX40 | Murine | Phase 1 | Unknown | NCT01644968 | Advanced cancer |
| IgG1 | Phase 1/2 | Recruiting | NCT01862900 | Metastatic breast, lung and liver cancer | ||
| Phase 1 | Recruiting | NCT02274155 | HNC | |||
| Phase 1/2 | Recruiting | NCT01303705 | Prostate cancer | |||
| Phase 1/2 | Recruiting | NCT02205333 | Advanced solid tumors | |||
| MEDI0562 | OX40 | IgG1 humanized Agonist | Phase 1 | Recruiting | NCT02318394 | Solid tumors |
| CP-870,893 | CD40 | IgG2 | Phase 1 | Completed | NCT01103635 | Recurrent/IV melanoma |
| Agonist | Phase 1 | Completed | NCT00607048 | Neoplasms | ||
| Phase 1 | Completed | NCT02225002 | Advanced solid tumors | |||
| Phase 1 | Active | NCT01008527 | Melanoma | |||
| Phase 0 | Completed | NCT02157831 | Solid tumors | |||
| Phase 1 | Completed | NCT01456585 | Adenocarcinoma | |||
| Phase 1 | Completed | NCT00711191 | Pancreatic neoplasm | |||
| PG102 FFP104 | CD40 | IgG4 Antagonist | Terminated (poor recruitment) | NCT00787137 | Psoriatic arthritis | |
| Lucatumumab HCD122 | CD40 | IgG1 Antagonist | Phase 2 Phase 1 | Completed Terminated | NCT00231166 NCT00108108 | Multiple myeloma CLL |
| Chi Lob 7/4 | CD40 | IgG1 chimeric Agonist | Phase 1 | Completed | NCT01561911 | Cancer, lymphoma |
| ASKP1240 | CD40 | IgG4 Antagonist | Phase 1 Phase 2 Phase 2 | Completed Completed Active | NCT01565681 NCT01585233 NCT01780844 | Healthy volunteers Psoriasis Kidney transplantation |
| Enavatuzumab PDL192 | Fn14 | IgG1 humanized | Phase 1 | Completed | NCT00738764 | Advanced solid tumors |
| Conatumumab AMG655 | TRAILR2/DR5 | IgG1 Agonist | Phase 1b Phase 1b/2 Phase 1b/2 Phase 1b/2 Phase 1b/2 Phase 1b/2 Phase 2 Phase 2 Phase 1b/2 | Completed Completed Terminated Completed Completed Completed Completed Ongoing Completed | NCT00791011 NCT00625651 NCT00819169 NCT00626704 NCT00534027 NCT00630552 NCT00813605 NCT01327612 NCT00630786 | Lymphoma CRC Solid tumors Sarcoma NSCLC Pancreatic cancer Metastatic CRC Solid tumors, lymphoma CRC |
| Lexatumumab HGS-ETR2 | TRAILR2/DR5 | IgG1 Agonist | Phase 1 | Completed | NCT00428272 | Sarcoma neuroblastoma |
| Mapatumumab HGS-ETR1 | TRAILR1/DR4 | IgG1 Agonist | Phase 2 Phase 2 | Completed Completed | NCT00092924 NCT00094848 | NSCLC NHL |
| Tigatuzumab | TRAILR2/DR5 | IgG1 humanized | Phase 1 | Completed | NCT01220999 | CRC neoplasms |
| CS-1008 | Agonist | Phase 2 | Ongoing | NCT01307891 | Breast cancer | |
| Phase 2 | Terminated | NCT00969033 | Metastatic CRC | |||
| Phase 2 | Completed | NCT00991796 | NSCLC | |||
| Phase 2 | Completed | NCT00521404 | Pancreatic cancer | |||
| Phase 2 | Completed | NCT00945191 | OC | |||
| Phase 1 | Completed | NCT01124630 | Metastatic CRC | |||
| Phase 2 | Ongoing | NCT01033240 | Liver cancer | |||
| Phase 1 | Completed | NCT00320827 | Malignancies, lymphoma | |||
| Drozitumab | TRAILR2/DR5 | IgG1 | Phase 2 | Terminated | NCT00543712 | Chondrosarcoma |
| PRO95780 | Agonist | Phase 2 | Completed | NCT00480831 | NSCLC | |
| Phase 1 | Completed | NCT00497497 | CRC | |||
| Phase 2 | Completed | NCT00517049 | NHL | |||
| Phase 1 | Completed | NCT00851136 | Metastatic CRC | |||
| LBY135 | TRAILR2/DR5 | IgG1 chimeric Agonist | Sharma et al.159 | Advanced solid tumors | ||
| TAS266 | TRAILR2/DR5 | Tetrameric nanobody | Phase 1 | Terminated | NCT01529307 | Advanced solid tumors |
Abbreviations: CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; HNC, head and neck cancer; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; OC, ovarian cancer